DMSO's toxicity extends to the epigenetic level with a paradoxical effect. It can upregulate enzymes that add methyl groups (hypermethylation), silencing genes, while also promoting enzymes that remove them (hypomethylation), activating others. This disruption creates widespread genomic instability with unknown long-term consequences for cell therapy products.

The focus in advanced therapies has shifted dramatically. While earlier years were about proving clinical and technological efficacy, the current risk-averse funding climate has forced the sector to prioritize commercial viability, scalability, and the industrialization of manufacturing processes to ensure long-term sustainability.

While the FDA is often blamed for high trial costs, a major culprit is the consolidated Clinical Research Organization (CRO) market. These entrenched players lack incentives to adopt modern, cost-saving technologies, creating a structural bottleneck that prevents regulatory modernization from translating into cheaper and faster trials.

Standard post-thaw viability tests are misleading for cell therapies. DMSO can cause profound, non-lethal damage by altering gene expression, inducing differentiation in stem cells, and impairing T-cell function. Cells may be 'alive' but therapeutically impotent, a risk not captured by simple viability metrics.

Our ability to generate and test therapeutic hypotheses in silico is rapidly outpacing the slow, expensive conventional clinical trial system. Without regulatory reform, the pipeline of promising drugs will remain stuck, preventing breakthroughs from reaching patients. The science is solvable; the system is not.

The problem is unique because engineering improvements, like faster temperature modulation, can lessen biological hurdles. For instance, more rapid cooling reduces the time spent in the 'danger zone' for ice crystal formation, thereby lowering the required concentration of potentially toxic cryoprotectant agents. This creates powerful leverage not common in biology.

A 'healthy tension' exists between research teams, who want to continually iterate on a therapy's design, and manufacturing teams, who need a finalized process to scale production for trials. Knowing precisely when to 'lock down' the design is a critical, yet difficult, decision point for successful commercialization.

Reversible cryopreservation is already a reality for human embryos, which have remained viable after 30 years in storage. The central challenge for companies like Until is not a fundamental scientific breakthrough, but rather solving the complex engineering problems of applying this proven concept to larger biological systems like organs.

Despite the clear potential of hybrid peptide-antibody drugs, their development is slow. This is attributed to human nature in science: researchers tend to stick with familiar, comfortable modalities and the tools available in their specific lab or company, creating a barrier to cross-disciplinary innovation.